Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,910.00    6.50 (0.34%)
Bid:
1,909.50
Ask:
1,910.50
Spread: 1.00 (0.052%)
Market Cap: £76.57b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Amendment - Director/PDMR Shareholding

16 Apr 2024 14:11

RNS Number : 8437K
GSK PLC
16 April 2024
 

The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K:

- A typographical correction to the share price for the transaction shown in the table below.

All other details to the original announcement remain unchanged.

The amended table is shown below.

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Amendment

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.3860

19

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2024-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHXQLFFZZLBBBD
Date   Source Headline
28th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st Aug 20243:30 pmRNSDirector/PDMR Shareholding
20th Aug 20243:30 pmRNSDirector/PDMR Shareholding
20th Aug 20247:00 amRNSB7-H3 ADC US FDA Breakthrough Therapy Designation
16th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
12th Aug 20243:30 pmRNSDirector/PDMR Shareholding
6th Aug 20247:00 amRNSStatement: Zantac (ranitidine) litigation
2nd Aug 20247:00 amRNSFDA Expands Jemperli Approval
1st Aug 20243:00 pmRNSTotal Voting Rights
31st Jul 20247:00 amRNS2nd Quarter Results
29th Jul 20248:18 amRNSStatement: Zantac (ranitidine) litigation
29th Jul 20247:00 amRNSCHMP positive opinion on Arexvy for 50-59 at risk
19th Jul 202410:36 amRNSBlenrep EMA Filing Acceptance
18th Jul 20243:30 pmRNSDirector/PDMR Shareholding
16th Jul 20243:30 pmRNSDirector/PDMR Shareholding
15th Jul 20243:30 pmRNSDirector/PDMR Shareholding
12th Jul 20243:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20247:00 amRNSGSK and CureVac collaboration restructured
1st Jul 20243:00 pmRNSTotal Voting Rights
28th Jun 20245:37 pmRNSStatement: Zantac (ranitidine) litigation
24th Jun 20247:05 amRNSOmjjara approved in Japan for myelofibrosis
24th Jun 20247:00 amRNSEMA validates Jemperli marketing authorisation
21st Jun 20243:30 pmRNSDirector/PDMR Shareholding
12th Jun 20243:30 pmRNSDirector/PDMR Shareholding
11th Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
10th Jun 20246:27 pmRNSStatement: Zantac (ranitidine) litigation
10th Jun 20247:00 amRNSFDA approves Arexvy for adults 50-59 at risk
3rd Jun 20243:00 pmRNSTotal Voting Rights
3rd Jun 20241:03 pmRNSUnprecedented results in Jemperli trial continue
3rd Jun 20247:05 amRNSASCO positive Blenrep DREAMM-8 trial results
3rd Jun 20247:00 amRNSStatement: Zantac (ranitidine) litigation
24th May 20247:00 amRNSStatement: Zantac (ranitidine) litigation
21st May 20247:00 amRNSPositive phase III asthma results for depemokimab
20th May 20243:30 pmRNSDirector/PDMR Shareholding
17th May 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th May 20244:42 pmRNSGSK announces intention to sell shares in Haleon
14th May 20243:30 pmRNSDirector/PDMR Shareholding
13th May 20243:00 pmRNSBlock listing Interim Review
8th May 20246:21 pmRNSResult of AGM
8th May 20244:57 pmRNSBoard Committee Change
3rd May 20243:30 pmRNSDirector/PDMR Shareholding
1st May 20243:00 pmRNSTotal Voting Rights
1st May 20247:00 amRNS1st Quarter Results
24th Apr 20247:00 amRNSUS FDA accepts new indication filing for Jemperli
19th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20243:30 pmRNSDirector/PDMR Shareholding
17th Apr 20247:05 amRNSGSK announces additional EAGLE-1 results
17th Apr 20247:00 amRNSResults from long-term data relating to Shingrix
16th Apr 20242:11 pmRNSAmendment - Director/PDMR Shareholding
16th Apr 20247:00 amRNSFDA accepts GSK meningitis vaccine candidate file

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.